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We often want to know which metal will bind to a protein most readily, which metal
or metals actually bind in vivo, and which one will be the best at enzymatic catalysis.
It is not guaranteed that a single metal could satisfy all of the above for a given natural
metalloenzyme. For artificial metalloenzymes (ArMs), we also want to know if the protein
can bind the desired metal, and if the metal would then function as a catalyst with the
desired activity and selectivity. Hence, being able to compute the metal binding affinities to
proteins is desirable in the studies of enzymatic catalysis and enzyme design. Unfortunately,
this goal is non-trivial. Efforts toward solving this problem are the focus of this article.
The first step to determine metal affinity is to identify the metal binding site, yet as this
is already firmly established for the functional metals of many interesting systems we will not
extensively cover it here. Other papers discuss the development of computational tools to ad-
dress this particular problem for unstudied, poorly resolved, or less accessible biomolecules.
While some of these methods can start from a sequence,1,2 all eventually require some sort
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of structure to identify possible binding sites.3–5 With this constraint, X-ray crystallography
remains the most reliable and broadly applicable approach for proteins, even if costly. As
with protein folds in general, crystal structures gathered over the last 50 years provide the
most likely binding site for a broad range of proteins. As many natural metalloenzymes bind
their strongly held metals alongside specifically tailored cofactors, substrates, and scaffolds
the likelihood of other significant binding sites is frequently minimal. However, static struc-
tures determined for a predominant metal do not answer all questions of metal affinity and
function.
The questions of which metal is used in a natural enzyme, and which metal we want
to employ in an artificial enzyme are not easily answerable because different forces drive
the evolution of enzymes in nature than the priorities of man-made catalysts. Instead of
maximizing enzyme activity, biology caps it to maintain the complex equilibria of homeosta-
sis. Biology prioritizes the bio-availability of the starting materials and fold stability, but
also ensures that enzymes can be readily destroyed when needed. These constraints also
apply to the way in which metals are selected for natural metalloenzymes.6,7 Furthermore,
the catalytically relevant metals for many metalloproteins are not truly known. Many en-
zymes are assumed to be Zn(II)-dependent based on X-ray crystal structures, but this can
be an artifact of experimental conditions.8 Follow up studies on systems such as histone
deacetylase9,10 carbonic anhydrase,8 S-ribosylhomocysteinase,11 and peptide deformylase12
show that sometimes other metals can bind and report significant activity. In some cases,
the metal reported by crystallography is not even a particularly significant contributor to
the proteins function. Without considering the binding affinity of different metals, in vitro
and computational studies of metalloproteins could be based on a false or incomplete picture
of metal preferences.
A major goal in the design of artificial metalloenzymes is maximal catalytic performance,
with less emphasis on stability in their simpler in vitro environment of operation. Previous
efforts already found that while proteins provide powerful platforms for new catalysts, the
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reactions they can perform, and sometimes their catalytic rates, have hard limitations.13,14
Recently, directed evolution has become an indispensable tool to develop new ArMs or
refine existing ones.15–19 However, directed evolution is constrained by the roles for which
a given protein scaffold has evolved.13,14,20 While there is promiscuity of function in many
proteins, some reactions are simply out of reach of conventional methodologies. Metals that
are not natively bioavailable can expand the space of accessible reactions. For example,
recent efforts show that noble metals can expand the repertoire of porphyrin-dependent
enzymes.21 However, non-physiological metals must bind sufficiently strongly to their protein
scaffolds, whose amino acids did not originally evolve to ligate non-physiological metals.
Thus, determination of metal affinity is required. Additionally, as we will show shortly,
the affinity of the metal to the protein (e.g. the stability gain upon metal binding) and
the catalytic activity may follow a non-trivial and non-linear mutual dependence, via the
Brønsted-Evans-Polanyi (BEP) relation.
Lastly, metal-protein affinity is of broader interest than biocatalysis. It is relevant to
metal transport about the body, particularly the activity of metal chaperones, which, unlike
many proteins, bind metals in a highly selective manner and in specific environments.22–25
Chaperones help maintain the distinct metal concentrations in different organ systems, tis-
sues, and even different subcellular organelles within cells.26 Tracking the metal affinity of
these proteins in different contexts is important for metal toxicology. A large number of
transition and heavy metals are now bioavailable with their use in modern industries, in-
cluding industrial catalysis. Some metals, such as Cd(II), Hg(II), As(III), and Pb(II) are
highly toxic and lead to non-specific syndromes.27,28 The extent of cytotoxicity of other met-
als, such as Al(III), Ti(IV), and Ga(III), is unclear but demands investigation as they are
introduced into the body both from the environment, and for medical purposes.29–33 Metal
binding may even play a role in neurodegenerative diseases, hypothetically facilitating the
protein-protein aggregation and fibril formation.34 Ultimately it is of high interest to know
the metal-protein affinity, and have ways to calculate it.
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1 Existing Methods and Their Limitations
Dedicated computational tools to investigate protein-metal binding, which we will refer to
as competitive metal affinity (CMA) methods, are hard to come by. The ideal CMA would
incorporate an accurate energy evaluation and significant dynamical sampling to capture
configurational entropy in order to fully describe the thermodynamics of metal binding.
Clearly, the expense of the accurate energy calculations severely limits the amount of sam-
pling that can be afforded. While there are many methods to study metalloprotein behavior
in general, not all are suited to form the basis of a CMA method.
Classical force field based methods can be parameterized to model some metalloenzyme
structures, but are typically insufficient to obtain thermodynamic values. Force field pa-
rameters for metals are based on a point charge supplemented with various harmonic terms
and operate on the basis of a fixed metal coordination (e.g. octahedral, tetrahedral) that
cannot change significantly as a function of protein dynamics. These potentials can contain
bonding and non-bonding interactions, but are generally fitted to capture structure (within
limits) rather than energy.35–38 In this respect they can be fairly successful for systems con-
taining closed shell metals with ideal geometries (Zn(II), Mg(II), Mn(II), Cd(II)), remaining
stable over long molecular dynamics (MD) simulations and providing some thermodynamic
data.39–41 However, even the most successful applications of these methods do not obtain
reliable energies for catalytic studies.
Electronic structure calculations are necessary to obtain accurate metal binding energies.
One possible approach is to use a small cluster model of the active site and treat it quantum
mechanically. However, this approach ignores the entropy of the protein scaffold and the
impact of the protein dynamics on the energy and entropy of the active site. The only
portion of the entropy in the free energy of the active site that this approach captures
is the vibrational entropy — typically calculated within the harmonic approximation and
subject to the constraints imposed by the rest of the protein structure. While cluster models
are useful for catalytic mechanism mapping,42,43 and as such can play a role in artificial
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metalloenzyme design,44–46 these applications rely on the cancellation of errors when protein
entropy is ignored equivalently throughout the reaction profile. On the other hand, many
metal exchange phenomena are inaccessible to the approach, as enzymes frequently undergo
some amount of restructuring when a new metal binds.
A more promising avenue to obtain metal binding free energies based on electronic struc-
ture calculations are mixed QM/MM simulations. This class of methods combines a quantum
mechanical description of the metal center and its surrounding environment and molecular
mechanical modeling of the rest of the protein (Figure 1). Statistical mechanical sampling
of the protein becomes possible within QM/MM, and there has been intensive research into
and development of these methods over the last two decades.47–49 Sufficient sampling is
still a problem, however, for most established QM/MM methods. Our group developed the
QM/DMD method,50 which combines DFT with discrete molecular dynamics (DMD)51 for
enhanced sampling. DMD is based on simplified square-well potentials, ballistic equations
of motion, and slight coarse graining, which permit extensive conformational sampling of
the full protein. QM/DMD divides the protein into three regions: a QM only region com-
prising the metal center(s) and ligating atoms, a DMD only region comprising the bulk of
the protein, and a region treated with both QM and DMD made up of the rest of the active
site (normally composed of 50 to 200 atoms). The overlapping region modeled with both
theories allows the geometric and energetic information to pass between QM and DMD cal-
culations. Typically, one step of a QM/DMD simulation involves 10,000 DMD steps followed
by a loosely converged DFT geometry optimization. We have used QM/DMD to successfully
study many aspects of metalloprotein behavior, including the effect of mutagenesis on struc-
ture and function,50,52,53 metal-dependent catalytic activity,10,54–56 redox functionality,50,57
and recently, metal affinity.10,58 Because of the sampling efficiency and capability of dynam-
ically changing the metal coordination sphere, QM/DMD is suitable for building a CMA
technology.
The exact form of the necessary free energy terms is another major complication in
5
Cα
Cα
Cβ
Cβ
Cβ
Cβ
QM
QM/MM
MM
A B
Figure 1: Diagrams demonstrating the active space of (A) QM/MM and (B) small cluster
methods. QM/MM models the entire protein, with QM for the active site (the dark and
light gray regions) and MM for the rest of the protein (the white region). In some forms
of QM/MM, such as QM/DMD, there is an overlapping region treated with both QM and
MM (in light gray) and MM modeling is only excluded from a small central region (in the
case of this diagram, the metal and its first coordination sphere in dark gray). Small cluster
methods, by contrast, only model the QM region.
CMA evaluation. One would think that metal affinities could be calculated from some
combination of the free energies of the bound metalloprotein, and the apo-protein and the
solvated metal ion. This is the approach of standard tools for free energy calculation in
QM/MM biomolecular simulations59,60 including adaptations of thermodynamic integration
(TI)61 and free energy perturbation (FEP).62 These methods cannot be simply applied
to metal binding processes. First, while it would be attractive for metal swapping, there
is no accurate way to perform an alchemical transformation directly from one metal to
another owing to their distinct electronic structures. Barring this, to obtain metal affinities
these methods would need to model the process of metal binding from solution to protein.
However, the accuracy of the free energies for these states will depend on the precision
of evaluating the entropy change upon binding, which requires complete sampling of the
conformational space of the protein both with and without the metal. Such full equilibration
is practically impossible.63 Additionally, evaluations of the free energy of the solvated metal
ion requires expensive and laborious quantum mechanical treatment, explicit solvent, and
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sufficient sampling of solvent configurations (on the order of 106). As metals are charged,
ionic species, obtaining accurate, equilibrated results is more difficult than for the organic
molecules that TI and FEP are applied to. Furthermore, this charged nature means that
metal ion free energies cannot be directly obtained by experiment either.64–66 In what follows
we describe our CMA method that avoids all complications described in this paragraph. We
will discuss several diverse applications of the method, its current limitations, and propose
further directions to improve upon it. To the best of our knowledge, this technique is
unprecedented.
2 Thermodynamic CMA Method
Our method calculates the relative metal binding free energy, ∆∆G, with respect to one
metal chosen as a reference. For many applications, relative free energies are sufficient as
at least one metal is already known to bind. The approach combines QM/DMD sampling
with a semi-empirical thermodynamic cycle that avoids ill-defined terms. First, we employ
QM/DMD simulations run to convergence (on the order of 20-100 steps per replicate which
is approximately 10-50 ns of sampling within DMD) of the protein with each considered
metal. In the second step we determine the lowest energy QM region for each metal with
optimization of the low-lying structures to tighter convergence and calculate its Gibbs free
energy using the harmonic approximation. This approach concentrates on swiftly calculating
a limited, but accurate free energy term for the region about the metal rather than pursuing
an arduous and insufficiently accurate full protein free energy. Finally, we use these free
energies in a thermodynamic cycle shown in Figure 2. The cycle consists of the metal ions
going into the protein from a complex with a chelating agent (typically EDTA, which we
exclusively used in all systems described in this article) rather than directly from solution.
Hence, instead of using a dubious, calculated value for the free energy of a metal in solution,
this cycle uses computationally tractable metal-chelator complexes. The free energies of
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metal complexation from solution to the chelator are readily available from experiment. The
final step of the cycle cancels the chelator terms through the computed free energies of metal
exchange in the protein (from QM/DMD) and in the chelator complex (from ab initio or
DFT calculations and harmonic vibrational entropies). Closing the thermodynamic cycle
yields the ∆∆G of one metal, Ma, binding to the protein relative to the other metal, Mb.
This means that when comparing the results of this method to experiment, only the trend
can be reproduced, not the absolute free energies of metal binding.
Figure 2: Thermodynamic cycles for the relative free energy of metal binding method. The
left cycle of direct enzyme (ENZ) binding is intractable as the structure of free metal ions
in solution is not defined (dashed red boxes). The right cycle uses experimentally available
data for chelator (CLTR) binding to avoid this problem (dashed blue boxes). The sum of
this cycle and the easily calculated transition from CLTR to the protein (solid blue boxes)
gives the free energy of exchanging metals in the protein by canceling all the CLTR terms.
3 Method Benchmark
We have successfully applied the described CMA method to a series of problems of catalytic
and biological relevance. To illustrate the method’s performance and accuracy, we now
describe several diverse examples, each with principally different biological functionality and
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chemistry. We consider a mononuclear oxidase, a mononuclear metal-dependent hydrolase,
and a metal transporter protein.
Acireductone dioxygenase (ARD) can tightly bind different metals and performs different
reactions depending on which metal binds. The protein is involved in the methionine salvage
pathway and acts on the substrate 1,2-dihydroxy-3-keto-5-(methylthio)pentene, oxidizing it
to two possible sets of products.67,68 ARD bound with Ni(II) catalyzes the formation of
methylthiopropinate, while ARD bound with Fe(II) catalyzes the formation of 2-keto-4-
methylthiobutyric acid, a precursor of methionine (Figure 3).69 The bound metal does not
change the structure of the protein, or the way in which the substrate binds to it, as we
showed with QM/DMD. This means that the properties of the metal itself dictate catalytic
selectivity. As such, ARD is the subject of many mechanistic studies.55,70,71 We showed
that the mechanistic bifurcation relies on the differences in charge transfer from the metal
ligands, through the metal, and to the dioxygen bound to the substrate. Experimental
binding studies show that ARD has an appreciable affinity for both Ni(II) and Fe(II).72,73 The
measured activity and metal binding affinities together demonstrate that both ARD reactive
pathways are meaningful. The ARDs preference for the metal should then be context-
dependent. Hence, the relative affinity of ARD to Fe(II) versus Ni(II) in the absence of
other environmental factors is of interest.
The application of our CMA method to the catalytic metals in ARD, including Co(II),
is illustrated in Table 1. To calculate the binding affinities of Fe(II), Ni(II), and Co(II)
to ARD, we started with QM/DMD trajectories from our previous studies.55 We selected
the three lowest energy structures of the QM regions for each metal variant of ARD. We
tested all feasible spin states of the metals with further geometry optimizations on these
systems, looking for the multiplicity that minimizes the electronic energy. Our calculations
showed that the multiplicity of Fe(II) was a singlet or quintet (depending on the structure),
Ni(II) was a triplet, and Co(II) was a doublet. For each multiplicity we then performed
frequency calculations and selected the lowest free energy among them. The calculations
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Figure 3: The structure of ARD (PDB ID: 1ZRR) and its active site, and the mechanisms of
the metal-dependent reactions the protein can perform. The Ni(II) and Fe(II) bound forms
of ARD preferentially bind different substrates and therefore perform different reactions.
were done with Turbomole (version 6.6).74 The pure meta-GGA TPSS DFT functional75
with the D3 dispersion correction76 was used. The metal was treated with the triple-zeta
basis set def2-TZVPP while all other atoms were treated with the double-zeta def2-SVP
basis set. The conductor-like Screen Model (COSMO) with a constant dielectric of 20 was
used to approximate the screening and solvation effects in the partially buried active site
of the protein.77 We selected this value based on the precedent of our previous, successful
simulations of partially exposed active sites (such as the other examples we cover in this
article). These settings are consistent with the initial QM/DMD runs. The results correctly
capture that the affinity of the protein for Ni(II) is stronger than for Fe(II) and that ARD’s
affinity for Co(II) is about the same as for Fe(II). The quantitative difference between the
computational and experimental values is about 1 to 2 kcal/mol (Table 1). Note that this
approaches chemical accuracy (generally accepted as 1 kcal/mol) which is rarely achievable
with DFT.78,79 Given the many approximations needed along the way and despite the can-
cellation of errors in the relative calculations, the qualitative agreement with experiment we
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obtained is still satisfying.
Table 1: Table of the experimental (Dai and Chai) and calculated binding affinities to ARD.
The energies are relative to Fe(II), which correspondingly has a value of 0 kcal/mol. The
experimental values here are based on Boltzmann weighted ratios of molar metal content.
Fe(II) Ni(II) Co(II)
Dai (kcal/mol) 0.0 -1.23 -0.65
Chai (kcal/mol) 0.0 -0.28 N/A
Calc. (kcal/mol) 0.0 -3.76 0.38
Our next system is a histone deacetylase (HDAC), which is part of a class of enzymes
that remove acetyl groups from histone lysines and potentially some nonhistone proteins.80,81
Alongside histone acetyltransferases, which add acetyl groups, HDACs regulate how tightly
histones bind to DNA and therefore gene regulation.82–84 Overexpression of HDACs is as-
sociated with many pathologies, particularly cancer, while inhibition leads to the activation
of genes related to growth arrest and tumor cells.84,85 Consequently, many anti-cancer drugs
are HDAC inhibitors.86,87 Many of these bind to the transition metal center of their HDAC
targets, including FDA approved suberanilohydroxamic acid (Vorinostat)88 and FK228 (Ro-
midepsin).89 To reliably develop tighter binding drugs with computational methods, knowl-
edge of which metal or metals bind to HDAC is necessary.
The catalytically relevant metals for histone deacetylases are not well understood. Histor-
ically, researchers assumed that HDACs are Zn(II) enzymes on the basis of X-ray structures
and kinetic studies.90,91 While Zn(II) is clearly a catalytically active metal in HDACs, as
discussed earlier in this article, the promiscuity of metalloproteins means that crystallo-
graphic data does not preclude the relevance of other metals. Indeed, kinetic studies report
significant activity for both Co(II) and Fe(II) in HDAC8, with Co(II) showing much higher
activity than Zn(II).9 This variety in metals that HDAC8 can use has important implications
in traditional mechanistic studies.
Binding affinities from our method proved necessary to properly identify the catalytically
relevant metals besides Zn(II) in HDAC8 and calculate their activities. Our group recently
investigated the mechanism of HDAC8 and how it varies with physiologically abundant met-
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als (Zn(II), Fe(II), Co(II), Mn(II), Ni(II), and Mg(II)) (Figure 4).10 Pairing a traditional
transition state search with QM/DMD simulations, we mapped the mechanism and calcu-
lated the activation barrier of the reaction for each metal. However, these results do not
capture the experimental catalytic order and suggest that experimentally inactive Mn(II),
Ni(II), and Mg(II) are reactive. We theorized that the binding affinities of these metals to
HDAC8 contributes to their in-vitro catalytic activity. We calculated the ∆∆G for each
metal and combined this with our computed barriers (∆G‡) to get a series of Krel:
Krel = exp
(
−∆G
‡
RT
)
exp
(
−∆∆Gbinding
RT
)
which in contrast to the barriers, match the experimental catalytic order and identify Mn(II)
and Mg(II) as inactive (Table 2). The Krel of Ni(II) is the one outlier, with calculations
suggesting that it is highly reactive, driven by its predicted high ∆∆Gbinding rather than
∆G‡. Ultimately, our study of HDAC8 demonstrates the utility of our metal binding ∆∆G
method when the catalytic metal or metals of a natural metalloenzyme are not known.
Table 2: Table of the experimental kcat and calculated Krel values for HDAC8. While the
exact values are not comparable, the qualitative order of the two catalytic measures match.
Notice that Ni(II) is an exception, with the highest Krel despite its experimental inactivity.
Also note that Mg(II) and Mn(II) have Krel that are many orders of magnitude lower than
Co(II) meaning that they are consistent with their inactive experimental result.
Co(II) Zn(II) Fe(II) Ni(II) Mn(II) Mg(II)
Exp. kcat (s
−1) 1.2 0.90 0.48 N/A N/A N/A
Calc. Krel 7.64× 10−11 1.27× 10−11 1.75× 10−13 1.89× 10−8 1.37× 10−17 1.46× 10−23
As an aside, we further hypothesize that in some cases the metal binding affinity could
be a descriptor of enzymatic catalytic activity. Specifically, by the BEP principle,92,93 the
binding of the rate-determining intermediate to the active site should be neither too strong
not too weak for the maximal catalytic activity to emerge. On the other hand, the stability of
the active site itself and the metal ion in it should impact the stability of the intermediate of
interest. That is because both the binding energy of the metal to its ligands, and the binding
energy of the metal to the reaction intermediate depend on the energy and spatial extent of
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Figure 4: The structure of HDAC8 (PDB ID: 2V5W) and its active site with example
substrate, and the most plausible mechanism of the deacetylation reaction it performs.
the orbitals of the metal. Therefore, there should be some relationship between the affinity
of the protein to the metal and the catalytic activity of the metalloenzyme. We tested this
conjecture using the computational data that we generated for the different metal variants
of HDAC8, focusing just on the rate-determining, second step of the reaction (as shown in
Figure 4). We excluded Mg(II) from the dataset, since it is known from the experiment to
not bind appreciably to HDAC8. We correlate the ∆∆G of the metal ion binding to the
protein to the Boltzmann weighted reaction barriers e−Ea/RT (which are the calculated kcat
normalized to remove the pre-exponential factor which we may assume to be approximately
the same for all considered metals). The result is shown in Figure 5. We observe a classic
volcano plot (a standard of heterogeneous catalysis analysis for the last 50 years)94 that all
metals obey, even Ni(II), demonstrating peak activity for a binding affinity around that of
Zn(II). While we cannot assume that all metalloenzymes obey this sort of scaling relation,
this demonstrates the utility of CMAs for yet another catalytic application.
Human serum transferrin (hTF) is an example of how CMAs could be used in a different
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Figure 5: Volcano plot showing scaling relation of HDAC8 between binding ∆∆G and reac-
tion rate. We calculated the reaction rates as the Boltzmann weighted ratios between each
calculated kcat and the Co(II) reference. The plotted values are normalized to remove the
pre-exponential factor which we may assume to be approximately the same for all considered
metals. Notice how even Ni(II) is consistent with this trend.
context. This protein is not catalytic, but is interesting for the purpose of this article because
it can uptake and also release metals through pH dependent protein conformations with po-
tentially profound implications in metal toxicology. The protein natively moves iron into cells
by receptor-mediated endocytosis. Since it can cross the blood-brain barrier and its receptor
is overexpressed in some cancer cells, hTF brings its cargo into particularly sensitive parts
of the body.95,96 Alarmingly, in-vitro binding studies show that hTF can bind other metals
besides Fe(III),97–99 including the potentially cytotoxic Ti(IV), Al(III), and Ga(III).29,33 The
promiscuity of hTF is of medical concern as these toxic metals are increasingly bioavailable
with their use in modern industries, including in therapeutic drugs.32,33,100,101 Previous stud-
ies provide some structural details on how hTF transports metals, but none access its full
in-vivo activity. Two domains comprise the protein, each of which binds a single metal atom
between two, highly similar subdomain lobes. Crystal structures and X-ray absorption fine
structure spectroscopy studies of the N-terminal domain suggest that the lobes hinge open
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in the endosome environment (Figure 6).102 Such a conformational change encourages metal
release. Previous classical MD simulations could access protein opening,103,104 but not the
thermodynamic data about the metal release.
Figure 6: The structure of hTF and its active site in the closed and open forms of the
protein. The closed form is associated with the pH of the blood serum, while the open
form is associated with the low pH conditions of the endosome. The closed structure was
obtained by X-ray crystallography (PDB ID: 3V83), while the open structure was obtained
from computational studies.58
We used our CMA method to get the first insight into the toxic metal transport abilities
of hTF in-vivo conformational states. We calculated metal binding affinities relative to
physiological Fe(III) for Ti(IV), Co(III), Ga(III), Cr(III), Fe(II), Zn(II) in both uptake and
release implicated forms of hTF (Figure 7).58 The order of the binding affinities in the
uptake form of the protein are qualitatively consistent with experiment. Accordingly, as
Ti(IV), Co(III), Ga(III), and Cr(III) demonstrate ∆∆G that are negative or about 0 in this
form, our results show that hTF can uptake these given metals competitively with Fe(III).
In contrast, the results for the release states vary for these metals, with Co(III) and Cr(III)
reporting consistently large ∆∆G, but Ti(IV) and Ga(III) reporting small or negative ∆∆G
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in one form. This suggests that hTF releases Co(III) and Cr(III) much more readily than
Fe(III), but releases Ti(IV) and Ga(III) about as readily as Fe(III). Since Ti(IV) and Ga(III)
strongly bind to both the closed and open states, these cytotoxic metals may sequester some
of the protein. Further, our study identified the protein residues that are most likely to be
responsible for opening and closing at changing pH, as well as a collection of geometric and
electronic factors that are responsible for the different affinities of hTF to the studied metals.
Figure 7: Metal binding affinities to hTF from experiment (solid black line) and from our
method. All affinities are relative to Fe(III), which correspondingly has a value of 0 kcal/mol
for all lines. The experimental values are based on Boltzmann weighted ratios of binding
constants. The solid yellow line are the values from uptake form of the protein. Notice that
it matches the shape and order of the experimental line. Furthermore, note that Ti(IV),
Co(III), Ga(III), and Cr(III) all have values that are negative or around 0 for this line. The
dashed light blue and dark purple lines are the values from the release forms of the protein
(called ’Double’ and ’Prtr’). The difference between the two forms is minor, but significant;
the structure represented with the light blue line contains an additional water molecule in
its active site. Notice that for at least one of the dashed lines, both Ti(IV) and Ga(III) bind
about the same or better than Fe(III).
16
4 Limitations and Outlook
Further research into CMA methods is important, especially as our method is not without
limitations. Its reliance on chelating agents introduces other problems besides limiting cal-
culations to referential ∆∆G. The best way to calculate the thermodynamic terms involving
the chelating agent is unclear. Experimental stability constants for EDTA and many re-
lated chelating agents are fortunately available for most metals in their common oxidation
states.105 Unfortunately, the corresponding structures of these metal complexes are not fully
known, and they are necessary to accurately calculate the free energy associated with the
transition from the chelator complex to the protein. In the studies we discuss above, we
assume full chelation of each metal with no other ligands in the complexes. This makes most
metals conform to an octahedral geometry. This is likely fine for large transition metals,
but breaks down for small and low charge metals such as Li(I) and Mg(II). Indeed, crystal-
lographic studies of Mg-EDTA binding show that a water molecule is also a ligand in the
complex.106 One way to mitigate these problems would be a benchmark study of a wide
range of chelators on a system that has been experimentally well characterized for many
metals. Calculating the set of ∆∆G for each chelator without varying any other parameters
would reveal which chelator can be used most accurately for each metal.
Our method is also limited to proteins which undergo only minor conformational changes
upon the binding of different metals. The first concern here is that the QM regions must
share the same atoms besides the metal center to satisfy the thermodynamic cycle. Metals
that bind entirely different sites on a protein are consequentially inaccessible to our current
method. A second concern largely involves computational scaling, as significant rearrange-
ment (like refolding) upon metal binding requires even more expensive structural sampling
in order to accurately assess the entropy component of ∆∆G. While this is a general prob-
lem with protein and metalloprotein simulations, enhanced sampling for the specific purpose
of metal binding affinities would be impactful. Solutions to both of these concerns would
render many systems more accessible, particularly metal chaperones as these proteins can
17
adopt different folds for different metals.24
Our current CMA is also limited in accuracy and chemical scope by its use of DFT. Tra-
ditionally, DFT struggles with multireference systems, where one Slater determinant or con-
figuration state function is insufficient, especially metal clusters. Certain post-Hartree-Fock
wavefunction methods can appropriately treat these cases and are particularly important for
accurate energies. There is already much discussion on the use of these tools in heteroge-
neous catalysis.107 As multireference post-Hartree-Fock methods tend to be computationally
intensive, multiconfiguration pair-density functional theory that blends wavefunction meth-
ods with DFT is promising for CMA applications because of their affordability.108 Future
CMAs could use such methods specifically for the free energy calculations on the QM region
to obtain more accurate energies without increasing computational cost too drastically.
Further advancements in CMA methods would greatly propel understanding of natural
metalloenzymes and the design of new ArMs. Such techniques could determine the cat-
alytically relevant metals in natural metalloenzymes, which cannot be taken for granted
from crystal structures. CMA calculations would be indispensable in the effort to better
understand metal transport pathways throughout the body, especially with regards to metal
toxicology. In the design of ArMs, replacing the bound metal in an existing metalloprotein
scaffold can introduce new functions, often inaccessible to current design methodologies like
directed evolution. Placing a metal into a specifically designed artificial scaffold is also an
attractive opportunity for ArMs catalysis. For all such design tasks, it is critical to assess
the metal affinity and its ability to outperform other metals that might be present in the
synthesis conditions. New tools such as CMAs will expand the catalytic space of metalloen-
zymes.
18
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